FDA approves Owlet’s baby-monitoring sock two years after halting sales
. The $299 wearable is available direct from the company and through a number of other retailers without a prescription, but it lacks the advanced features that set it apart from the rest of its rivals. Instead, it’s a pretty straightforward sleep tracker.
BabySat, on the other hand, is a prescription device. It integrates medical-grade pulse oximetry technology into a discreet wearable. It’s a noninvasive tool to measure how well oxygen is circulating to extremities in babies from 1 to 18 months. Without a prescription, a rival medical-grade device can not be readily found on the market, given that BabySat is the first device of its kind to receive FDA approval. Creating a treatment plan with a doctor is especially valuable and useful to the parents of babies that have been diagnosed with heart defects or chronic conditions. If a newborn or baby does present with persistent low oxygen levels, quick intervention by medical professionals is needed to prevent life-threatening complications.
Owlet anticipates the product will be available in the US by the end of this year. The company declined to disclose pricing information for BabySat but did say that insurance options, including reimbursements and HSA/FSA eligibility, will likely be available at launch. All products recommended by Engadget are selected by our editorial team, independent of our parent company. Some of our stories include affiliate links. If you buy something through one of these links, we may earn an affiliate commission. All prices are correct at the time of publishing.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FDA OKs Drug for Cholestatic Pruritus in Alagille SyndromeOdevixibat is indicated for treatment of cholestatic pruritus associated with Alagille syndrome in patients as young as 12 months. It marks the second indication for the drug.
Lire la suite »
FDA OKs Low-Dose Colchicine for Broad CV IndicationThe drug represents the first specific anti-inflammatory drug for the reduction of cardiovascular events for patients with established atherosclerotic disease or with multiple risk factors.
Lire la suite »
FDA Warns of Tattoo Ink Tied to Dangerous InfectionsThe FDA released the new draft guidance aiming to reduce the use of pathogen-contaminated tattoo ink, which can cause stubborn infections that are especially hard to treat, dermatologists said.
Lire la suite »
FDA Approves Talazoparib for Metastatic Prostate CancerThe oral PARP inhibitor talazoparib in combination with enzalutamide provides a new treatment option for patients with HRR gene–mutated metastatic castration-resistant prostate cancer.
Lire la suite »
US FDA approves Eli Lilly-Boehringer's diabetes drugs for childrenThe U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim's drugs Jardiance and Synjardy to treat type 2 diabetes in children.
Lire la suite »
FDA to test out nutrition labels on the front of food packaging | CNNGetting nutritional information is not always as simple and convenient as it should be, experts say. The FDA is testing out new labels on the front of packages to try to combat that.
Lire la suite »